Journal of Medical Academics

Register      Login

VOLUME 3 , ISSUE 2 ( July-December, 2020 ) > List of Articles

REVIEW ARTICLE

Pharmacovigilance: Perspectives in India

Novy Gupte, Sapna Pradhan

Keywords : Adverse drug events, knowledge, attitudes, and practices, Adverse drug reactions, Pharmacogenomics, Pharmacovigilance, Pharmacovigilance program of India, Stakeholders

Citation Information : Gupte N, Pradhan S. Pharmacovigilance: Perspectives in India. Journal of Medical Academics 2020; 3 (2):59-62.

DOI: 10.5005/jp-journals-10070-0062

License: CC BY-NC 4.0

Published Online: 08-03-2021

Copyright Statement:  Copyright © 2020; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Background: Adverse drug reactions are a significant burden on the health system across the world. Paradoxically, a considerable chunk of ADRs is missed or not reported on account of avoidable reasons, resulting in bottlenecks in carrying out the proper management. This problem is much more evident in India and other resource-limited communities than in the prosperous countries of the West. Aim and objective: To provide a state-of-the-art update on pharmacovigilance with special reference to perspectives in India and make appropriate recommendations for improving ADR reporting. Design: The contents are based on a review of English medical literature augmented with the author\'s first-hand experience in the field over the past more than a decade. Results: Well-organized pharmacovigilance started in India with the launching of the Pharmacovigilance Programme of India in 2010. Despite it making a perceptible improvement in ADR reporting, high underreporting of ADRs still prevails. The yet greater thrust on inculcating awareness comprising knowledge attitudes and practices among the healthcare professionals is likely to lead to further improvement in ADR reporting, resulting in augmentation of the safe use of drugs. Conclusion: Pharmacovigilance, a mandatory drug safety activity, needs to be propagated with yet greater vigor among healthcare professionals in India.


PDF Share
  1. Causality assessment in cancer chemotherapy-induced adverse drug reactions in a tertiary-care centre in North India. ECPharmacol Toxicol 2010;7:74-85.
  2. Undereporting of adverse drug reactions: a challenge for pharmacovigilance in India. Indian J Pharmacol 2015;47(1):65-71. DOI: 10.4103/0253-7613.150344.
  3. Online reporting of adverse drug reactions: a study from a French regional pharmacovigilance center. Therapie 2014;69(5):395-400. DOI: 10.2515/therapie/2014035.
  4. Reporting of adverse drug reactions in India: a review of the current scenario, obstacles and possible solutions. Int J Risk Safe Med 2019;30(1):33-34. DOI: 10.3233/JRS-180025.
  5. Available at: https://www.who.int/medicines/areas/quality_safety/safety_efficacy/pharmvigi/en/ Accessed on: 20 December 2020.
  6. Pharmacovigilence practice for safety of medication system in India. J Phytopharmaco 2018;7:216-221.
  7. Available at: https://www.genome.gov/FAQ/Pharmacogenomics Accessed on 22 December 2020.
  8. Role of pharmacovigilance in India. Online J Publ Health 2015;7:e23.
  9. Pharmacovigilance Program of India: recent developments and future perspectives. Indian J Pharmacol 2016;48(6):624-628. DOI: 10.4103/0253-7613.194855.
  10. Pharmacovigilance-related “knowledge, attitudes and practices among institutional doctors: questionnaire-based study. JEC Pharmacology Toxicol (London), In press.
  11. A survey on knowledge, attitude and practice of pharmacovigilance towards adverse drug reactions reporting among doctors and nurses in a tertiary care hospital in South India. J Young Pharm 2016;8(4):471-476. DOI: 10.5530/jyp.2016.4.25.
  12. An evaluation of knowledge, attitude, and practice of adverse drug reaction reporting among prescribers at a tertiary care hospital. Perspectives in Clin Res 2011;2(4):129-136. DOI: 10.4103/2229-3485.86883.
  13. A questionnaire study on the knowledge, attitude, and the practice of pharmacovigilance among the healthcare professionals in a teaching hospital in South India. Perspect Clin Res 2015;6(1):45-52. DOI: 10.4103/2229-3485.148816.
  14. Knowledge, attitudes, and practice of doctors to adverse drug reaction reporting in a teaching hospital in India: an observational study. J Nat Sci Biol Med 2013;4(1):191-196. DOI: 10.4103/0976-9668.107289.
  15. Available at: http://journals.plos.org/plosone/ Accessed on: 25 December 2020.
  16. Knowledge, attitude, and practice of pharmacovigilance among the healthcare professionals in a tertiary care hospital – A questionnaire study. Biomed Pharmacol J 2017. 10. Available at http://biomedpharmajournal.org/?p=16563. Accessed on: 25 December 2020.
  17. Knowledge, attitude and perception/practices (KAP) of medical practitioners in India towards adverse drug reaction (ADR) reporting. Perspect Clin Res 2012;3(3):90-94. DOI: 10.4103/2229-3485.100651.
  18. Adverse drug reaction reporting and pharmacovigilance: knowledge, attitudes and perceptions among the resident doctors. J Pharm Sci Res 2011;3:1064-1069.
  19. Knowledge, attitude and practices associated with adverse drug reaction reporting amongst doctors in a teaching hospital. Int J Risk Saf Med 2011;23: 227-232.
  20. Adverse drug reaction reporting: attitudes and perceptions of medical practitioners. Asian J Pharm Clin Res 2009;2:10-14.
  21. Pharmacovigilance: a study to evaluate knowledge, attitude, and practices of and impact of educational intervention among doctors in teaching hospital, in rural area of Jalna, India. Int J Basic Clin Pharmacol 2015;4:427-431.
  22. Awareness and perception experiences on adverse drug reaction among doctors, nurses and pharmacists of a tertiary care rural teaching hospital. Indian J Drugs Dis 2013;2:248-258.
  23. Knowledge, attitude and practice of pharmacovigilance among prescribers of Government Medical College and Hospital, Aurangabad (Maharashtra). Int J Pharm Ther 2013;3:10-18.
  24. The extent of awareness among the final year students, interns and postgraduates in a government teaching hospital. J Clin Diagn Res 2012;6(Suppl. 7):1248-1253.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.